Researchers saw 95% fewer cases than expected; model offered antiretroviral meds to HIV-infected members and preventive therapy for uninfected partners
Providing HIV medication to both members of a HIV-serodiscordant couple substantially reduced the risk of transmission within that couple, according to a study published Aug. 23 in PLOS Medicine.
The University of Washington is one of 56 DREAMS Innovation Challenge winners* announced on Monday by the U.S. President's Emergency Plan for AIDS Relief (PEPFAR); Janssen Pharmaceutica NV (Janssen), one of the Janssen pharmaceutical companies of Johnson & Johnson; and ViiV Healthcare.
New data analyses finds that a monthly vaginal ring containing an antiretroviral drug called dapivirine can cut women’s HIV risk by more than half and, in some, by 75 percent or more.
One of the researchers, Jared Baeten, a University of Washington professor of epidemiology, medicine and global health, presented the results Tuesday at the AIDS 2016 conference in Durban, South Africa.
By Lucy Tiven
On Tuesday, the Journal of the American Medical Association published a study on antiretroviral therapy (ART) and HIV transmission in mixed status couples — couples where one partner is HIV positive.
By Randy Dotinga
HealthDay Reporter
TUESDAY, July 12, 2016 (HealthDay News) -- HIV transmission is highly unlikely among straight couples who have sex without condoms when one partner carries the virus but takes medication, new research suggests.
For gay couples in the same scenario, the risk seems to be only slightly higher.
By Chelsea Gish
The ASPIRE trial and The Ring Study, two large scale clinical trials, have found that microbicides can safely reduce the risk of new HIV infections in women.
A microbicide is any compound capable of destroying microbes and infectious agents. Recently, this method of prevention has become particularly relevant in reducing the transmission of HIV when applied to the vaginal or rectal region as a topical gel.
...
A flexible and inexpensive ring that is inserted into the vagina, where it slowly releases an antiviral drug, helped protect African women against contracting H.I.V. from their sexual partners, researchers said Monday in reports on two major studies that included more than 4,500 women.
By Lisa Rossi
Two large clinical trials have found that a microbicide prevention method can safely help reduce new HIV infections in women.
Results of the ASPIRE trial, which enrolled more than 2,600 women in Africa, were announced today at the Conference on Retroviruses and Opportunistic Infections in Boston. The results also will be published online in the New England Journal of Medicine.
We are delighted to announce that Jared Baeten, MD, PhD has agreed to serve as Vice Chair for the Department of Global Health. Dr. Baeten, who is also a Professor in the Departments of Epidemiology and Medicine, has been conducting HIV- and STD-related research since 1997 and is widely respected for his leadership of clinical trials of interventions to prevent HIV transmission. As Vice Chair Dr.